Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Call Transcript November 5, 2024 Apellis Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.46 EPS, expectations were $-0.32. Operator: Good morning, ladies ...
DRI Healthcare Trust Reports Third Quarter 2024 Results
CNW/ - DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) ("DRI" or "the Trust") today announced its financial results for the ...
Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y
Apellis Pharmaceuticals, Inc. APLS incurred third-quarter 2024 loss of 46 cents per share, wider than the Zacks Consensus Estimate of a loss of 32 cents. The company had incurred a loss of $1.17 per ...
MedPage Today4d
FDA Grants Market Authorization to Light-Therapy System for Dry AMD
LumiThera's Valeda Light Delivery System generates light at different wavelengths to stimulate and improve the function of retinal mitochondria. The photobiomodulation (PBM) system is the first ...
FiercePharma4d
Drugs for unmet needs and those from experienced companies had the best chance for successful launches in 2023: report
What’s an example of a well-executed drug launch? Look no further than Reata’s commercialization of Skyclarys, the first ...
Business Insider5d
Hold Rating on Apellis Pharmaceuticals Amid Concerns Over Syfovre Sales and Market Challenges
The third-quarter results for 2024 have reinforced concerns about the slowing geographic atrophy market and the need to adjust expectations for Syfovre. Negative commentary on pricing and a more ...
Apellis Pharmaceuticals: Long-Term Growth Potential for Syfovre Despite Short-Term Sales Challenges
Apellis Pharmaceuticals (APLS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...
Why Apellis Pharmaceuticals Stock Was Tumbling on Tuesday
In late-session trading, investors were selling out of Apellis, to the point where its price was down by nearly 6%. By ...
Investor's Business Daily on MSN5d
Apellis Dives As Worse-Than-Expected Syfovre Sales Add Fuel To Market Woes
Apellis stock toppled Tuesday after third-quarter sales of the company's eye drug, Syfovre, widely missed Wall Street's expectations.Please watch the video at Investors.com - How To Buy Stocks: Ways ...
FiercePharma5d
Analysts point to Syfovre 'nadir' after Apellis discloses disappointing quarter
Despite witnessing modest growth in demand over the past three months, Apellis Pharmaceuticals’ complement inhibitor for ...
Apellis drops as disappointing Syfovre sales drive Q3 miss
Apellis Pharmaceuticals (APLS) stock falls as company's Q3 2024 financials disappoint with lower-than-expected U.S. sales ...
Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results
Generated $196.8 million in 3Q 2024 revenues, including $176.6 million in U.S. net product salesGrew SYFOVRE® (pegcetacoplan injection) demand by 7% quarter-over-quarter, with U.S. net product revenue ...